{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:11:28Z","timestamp":1780089088429,"version":"3.54.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005939","name":"Investigative Reporters and Editors","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["DM 737\/202"],"award-info":[{"award-number":["DM 737\/202"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004462","name":"National Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.isci.2025.111842","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T19:17:36Z","timestamp":1737400656000},"page":"111842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors"],"prefix":"10.1016","volume":"28","author":[{"given":"Giorgia","family":"Anastasio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Felaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Lamolinara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco del","family":"Pizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cacciagrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Mottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Mutarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Modugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8184-2856","authenticated-orcid":false,"given":"Luca","family":"Cardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.111842_bib1","doi-asserted-by":"crossref","unstructured":"Siegel, R.L., Giaquinto, A.N., Jemal, A. (2024). Cancer statistics. CA Cancer J. Clin. 74, 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820. Erratum in 2024. CA Cancer J. Clin. 74, 203. https:\/\/doi.org\/10.3322\/caac.21830.","DOI":"10.3322\/caac.21820"},{"key":"10.1016\/j.isci.2025.111842_bib2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","article-title":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","volume":"142","author":"Kanda","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2025.111842_bib3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI59227","article-title":"Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice","volume":"122","author":"Collins","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.isci.2025.111842_bib4","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1158\/0008-5472.CAN-19-0187","article-title":"Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS\u2013Dependent Pancreatic Ductal Adenocarcinoma","volume":"79","author":"Mottini","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2025.111842_bib5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","article-title":"A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival","volume":"15","author":"Singh","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2025.111842_bib6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","article-title":"Cancer drug discovery by repurposing: teaching new tricks to old dogs","volume":"34","author":"Gupta","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.isci.2025.111842_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcancer.2019.09.023","article-title":"Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets","volume":"68","author":"Mottini","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.isci.2025.111842_bib9","article-title":"Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors","volume":"1879","author":"Ye","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.isci.2025.111842_bib10","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-08-2196","article-title":"Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas","volume":"15","author":"Stewart","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.111842_bib11","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2025.111842_bib12","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","article-title":"Epigenetic Resensitization to Platinum in Ovarian Cancer","volume":"72","author":"Matei","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2025.111842_bib13","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1038\/s41467-023-42417-w","article-title":"DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts","volume":"14","author":"Goyal","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.111842_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.111842_bib15","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/MCB.01799-07","article-title":"DNA Methylation Inhibitor 5-Aza-2\u2032-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3B","volume":"28","author":"Palii","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.isci.2025.111842_bib16","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.18632\/oncotarget.1821","article-title":"The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma","volume":"5","author":"Maes","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2025.111842_bib17","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1093\/nar\/gku638","article-title":"The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2\u2019-deoxycytidine lesions","volume":"42","author":"Orta","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2025.111842_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113098","article-title":"Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment","volume":"42","author":"Yabushita","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2025.111842_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.isci.2025.111842_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.isci.2025.111842_bib21","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/s41598-020-59074-4","article-title":"The kinase polypharmacology landscape of clinical PARP inhibitors","volume":"10","author":"Antolin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.111842_bib22","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.isci.2025.111842_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ijc.31292","article-title":"Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models","volume":"143","author":"Golan","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2025.111842_bib24","doi-asserted-by":"crossref","first-page":"e9172","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.isci.2025.111842_bib25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","article-title":"Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents\u00a0\u2013 A Potential Therapy for Cancer","volume":"30","author":"Muvarak","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2025.111842_bib26","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1242\/jcs.128272","article-title":"Damage response of XRCC1 at sites of DNA single strand breaks is regulated by phosphorylation and ubiquitylation after degradation of poly(ADP-ribose)","volume":"126","author":"Wei","year":"2013","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.isci.2025.111842_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24670","article-title":"Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology","volume":"10","author":"Jan","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.isci.2025.111842_bib28","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/blood-2019-130579","article-title":"Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity","volume":"134","author":"Kishtagari","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.111842_bib29","first-page":"1693","article-title":"Additivity predicts the efficacy of most approved combination therapies for advanced cancer","volume":"4","author":"Hwangbo","year":"2023","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.isci.2025.111842_bib30","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1038\/s41467-018-07472-8","article-title":"Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis","volume":"9","author":"Santana-Codina","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.111842_bib31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.chembiol.2018.03.005","article-title":"Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers","volume":"25","author":"Koundinya","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.isci.2025.111842_bib32","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1042\/BCJ20160302","article-title":"The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine","volume":"473","author":"Requena","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.isci.2025.111842_bib33","first-page":"5536","article-title":"A Mammalian Cell\u00a0Line Deficient in Activity of the DNA Repair Enzyme 5-Hydroxymethyluracil-DNA Glycosylase Is Resistant to the Toxic Effects of the Thymidine Analog 5 -Hydroxymethyl-2\u2032-Deoxyuridine","volume":"12","author":"Boorstein","year":"1992","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.isci.2025.111842_bib34","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-18-0204","article-title":"An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations","volume":"24","author":"Pulliam","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.111842_bib35","doi-asserted-by":"crossref","first-page":"22609","DOI":"10.1073\/pnas.1903765116","article-title":"DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation","volume":"116","author":"Abbotts","year":"2019","journal-title":"USA"},{"key":"10.1016\/j.isci.2025.111842_bib36","doi-asserted-by":"crossref","first-page":"22429","DOI":"10.1073\/pnas.1916581116","article-title":"Epigenetic targeting of DNA repair in lung cancer","volume":"116","author":"Lok","year":"2019","journal-title":"USA"},{"key":"10.1016\/j.isci.2025.111842_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2020.102977","article-title":"Treatment of human cells with 5-aza-dC induces formation of PARP1-DNA covalent adducts at genomic regions targeted by DNMT1","volume":"96","author":"Kiianitsa","year":"2020","journal-title":"DNA Repair"},{"key":"10.1016\/j.isci.2025.111842_bib38","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.cell.2024.01.015","article-title":"PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends","volume":"187","author":"Chappidi","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.111842_bib39","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-21-3729","article-title":"Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed\/Refractory Acute Myeloid Leukemia","volume":"28","author":"Baer","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.111842_bib40","first-page":"6","article-title":"Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectives","volume":"38","author":"Toulany","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.isci.2025.111842_bib41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/1878-0261.12040","article-title":"Enhanced dependency of KRAS -mutant colorectal cancer cells on RAD 51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae","volume":"11","author":"Kalimutho","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.isci.2025.111842_bib42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.111842_bib43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.111842_bib44","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"Faseb. J."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225001026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225001026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:41:46Z","timestamp":1780087306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2589004225001026"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.111842","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.23.599676","asserted-by":"object"}]},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.111842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111842"}}